Overview
US biopharma firm's 2025 net loss narrowed from prior year
Company advanced pivotal Phase 3 REGAL trial and expanded SLS009 into earlier-line AML
Year-end cash position strengthened with $42.6 mln in Q1 2026 warrant proceeds
Outlook
SELLAS expects final analysis of Phase 3 REGAL trial after reaching 80 events
Company anticipates European enrollment for SLS009 clinical study in Q2 2026
SELLAS sees 2026 as a catalyst-rich year with continued clinical execution
Result Drivers
LOWER R&D SPENDING - Co said research and development expenses fell due to lower clinical trial and consulting costs after REGAL study enrollment completed
PIPELINE ADVANCEMENT - Co advanced pivotal Phase 3 REGAL trial and expanded SLS009 into earlier-line AML treatment
Company press release: ID:nGNX17w9L9
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income | -$26.86 mln | ||
FY Basic EPS | -$0.25 | ||
FY Operating Expenses | $28.27 mln | ||
FY Operating Income | -$28.27 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $7.50, about 51.5% above its March 18 closing price of $4.95
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)